We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease.
- Authors
Mimouni, Maroua; Bulsei, Julie; Darlington, Meryl; Estellat, Candice; Rouzet, François; Hyafil, Fabien; Durand-Zaleski, Isabelle; Chequer, Renata; Ducrocq, Gregory; Alfaiate, Toni; Regaieg, Hamza; Abtan, Jérémie; Leygnac, Sébastien; Milliner, Milan; Burg, Samuel; Azzouna, Rana Ben; Potier, Louis; Laouénan, Cédric; Quintin, Caroline; Roussel, Ronan
- Abstract
Background: 82-Rubidium-Positron emission tomography myocardial perfusion imaging (Rb-PET-MPI) offers higher diagnostic performance for the detection of myocardial ischemia compared to Tc-SPECT-MPI. The aim of this economic evaluation was to perform a cost-effectiveness analysis of Rb-PET-MPI versus Tc-SPECT-MPI in patients with suspected myocardial ischemia according to pretest probabilities (PTP) of obstructive coronary artery disease based on the results of the RUBIS Trial. Methods: Costs and effectiveness were calculated for all patients over 1 year and an incremental analysis of differences in costs and effectiveness in terms of diagnostic accuracy was performed. The uncertainty of the results was estimated using bootstrap. The analysis was conducted from the perspective of the French health care system with a time horizon of 12 months. Results: The average cost of a Rb-PET-MPI-based strategy for the detection of myocardial ischemia was €219 lower than a SPECT-MPI-based strategy (€1192 (± 1834) vs €973 (± 1939), p < 0.01). The one-year incremental cost-effectiveness ratio was negative: − €2730 (money saved per additional accurate diagnosis) in patients presenting PTP > 15% for the Rb-PET-MPI vs. Tc-SPECT-MPI strategy. Analysis of the joint distribution of costs and outcomes found that the Rb-PET-MPI strategy had a 92% probability to be dominant (cost-saving and outcome-improving). Conclusions: Rb-PET-MPI is cost-effective compared to Tc-SPECT-MPI for the detection of myocardial ischemia in patients with PTP > 15% of obstructive coronary artery disease. Trial registration: RUBIS Trial registration: NCT01679886, Registered 03 September 2012, https://clinicaltrials.gov/ct2/show/NCT01679886.
- Subjects
MYOCARDIAL perfusion imaging; CORONARY artery disease; MYOCARDIAL ischemia; COST effectiveness; DISTRIBUTION costs; MEDICAL care
- Publication
EJNMMI Research, 2023, Vol 13, Issue 1, p1
- ISSN
2191-219X
- Publication type
Article
- DOI
10.1186/s13550-023-00954-x